Qube Research & Technologies LTD Delcath Systems, Inc. Transaction History
Qube Research & Technologies LTD
- $72.9 Billion
- Q4 2024
A detailed history of Qube Research & Technologies LTD transactions in Delcath Systems, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 205,304 shares of DCTH stock, worth $2.58 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
205,304
Previous 76,311
169.04%
Holding current value
$2.58 Million
Previous $689,000
250.94%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding DCTH
# of Institutions
95Shares Held
11MCall Options Held
144KPut Options Held
57.4K-
Vivo Capital, LLC Palo Alto, CA1.71MShares$21.5 Million3.93% of portfolio
-
Aigh Capital Management LLC Baltimore, MD1.39MShares$17.4 Million6.61% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.22MShares$15.4 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT801KShares$10.1 Million0.66% of portfolio
-
Gilder Gagnon Howe & CO LLC New York, NY612KShares$7.7 Million0.08% of portfolio
About DELCATH SYSTEMS, INC.
- Ticker DCTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 8,597,680
- Market Cap $108M
- Description
- Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...